Skip to main content
Asclepix Therapeutics, Inc.Portfolio

Baltimore-based AsclepiX Therapeutics raises $5M

By November 15, 2018March 25th, 2021No Comments

Johns Hopkins spinout AsclepiX Therapeutics raised $5 million in new funding that will assist in development of new treatment for eye diseases that are leading causes of blindness in adults.

The convertible note round was led by Barer & Son Capital, with participation from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. It brings the company’s total raised to $11 million.

The company was founded by Johns Hopkins biomedical engineering professors Aleksander Popel and Jordan J. Green, who developed peptide products that form the foundation of the company’s treatments.

With a team of four people at JHU’s FastForward space in Remington’s R. House, Ascelpix is developing a treatment for diseases called diabetic macular edema and wet age-related macular degeneration. According to the company, the number of people with the treatment is expected to reach 7 million by 2020.

Currently available treatments require an injection into the eye once a month for several months. AsclepiX Therapeutics’ first treatment, called ATX107, offers the potential for treating the diseases with fewer injections.

“In extensive animal testing, AXT107 was safe and superior to current approved therapies in preventing and even reversing progressive pathologic changes in the retina with just two to three injections per year, a clear benefit in longer duration and less frequent dosing compared to those currently approved therapies,” said AsclepiX Therapeutics CEO Wendy Perrow.

The funding will assist the company as it seeks to complete its application for investigational new drug status with the U.S. Food and Drug Administration. The company is also planning for clinical trials for patients with diabetic macular edema and wet age-related macular degeneration.

With the investment, Barer and Sons Managing Partner Josh Barer, Rapha Capital Management Managing Partner Kevin Slawin, and Sapna Srivastava are joining the company’s board.

“Vision loss is a devastating complication of several common diseases, including diabetes. We’re excited at the potential of AXT107 to help millions avoid this difficult disability while requiring less frequent therapeutic interventions by their ophthalmologists,” Slawin said in a statement.

Rapha Capital Management, LLC is providing this website for informational purposes only. Nothing on this website is intended to constitute, or should be deemed to be, financial advisory, legal, tax, accounting or other professional advice to you or any other party; be an opinion of the appropriateness or suitability of any investment; or constitute an offer to sell or solicitation of an offer to buy any security or investment. This website and its content (collectively, “Content”) is intended for general informational purposes only and should not be acted upon without first obtaining financial advisory, legal, tax, accounting or other professional advice from your consultant or other professional with respect to your own personal investment objectives, financial circumstances and needs. Nothing on the Site shall be considered a recommendation or solicitation to buy or an offer to sell a security to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Any investment decisions you may make on the basis of any information found on this web site is your sole responsibility. Prior to making any investment or hiring any investment manager you should consult with a professional financial advisor, legal and tax advisor to assist in due diligence as may be appropriate and determining the appropriateness of the risk associated with a particular investment. In no event shall Rapha Capital Management, LLC be responsible or liable for the correctness of any such material or for any damage or lost opportunities resulting from use of these data.